A N Freedman

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention
    Andrew N Freedman
    Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7344, USA
    J Natl Cancer Inst 95:526-32. 2003
  2. pmc Colorectal cancer risk prediction tool for white men and women without known susceptibility
    Andrew N Freedman
    Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, EPN 4005 MSC 7344, Bethesda, MD 20892 7344, USA
    J Clin Oncol 27:686-93. 2009
  3. ncbi request reprint Cancer risk prediction models: a workshop on development, evaluation, and application
    Andrew N Freedman
    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 7344, USA
    J Natl Cancer Inst 97:715-23. 2005
  4. pmc Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation
    Andrew N Freedman
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7393, USA
    J Natl Cancer Inst 102:1698-705. 2010
  5. ncbi request reprint US physicians' attitudes toward genetic testing for cancer susceptibility
    A N Freedman
    Division of Cancer Control and Population Sciences, National Cancer Institute NIH, EPN 4005 MSC 7344, 6130 Executive Boulevard, Bethesda, MD 20892 7344, USA
    Am J Med Genet A 120:63-71. 2003
  6. pmc Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians
    L Wideroff
    Applied Research Program Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 7344, USA
    J Med Genet 42:749-55. 2005
  7. ncbi request reprint What factors are associated with diagnostic follow-up after abnormal mammograms? Findings from a U.S. National Survey
    K Robin Yabroff
    Health Services and Economics Branch Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda, MD 20892 7344, USA
    Cancer Epidemiol Biomarkers Prev 13:723-32. 2004
  8. pmc Five-year and lifetime risk of breast cancer among U.S. subpopulations: implications for magnetic resonance imaging screening
    Barry I Graubard
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 19:2430-6. 2010
  9. pmc Laypersons' responses to the communication of uncertainty regarding cancer risk estimates
    Paul K J Han
    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA
    Med Decis Making 29:391-403. 2009
  10. doi request reprint Conceptual problems in laypersons' understanding of individualized cancer risk: a qualitative study
    Paul K J Han
    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA
    Health Expect 12:4-17. 2009

Detail Information

Publications16

  1. ncbi request reprint Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention
    Andrew N Freedman
    Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7344, USA
    J Natl Cancer Inst 95:526-32. 2003
    ..67% or higher for breast cancer chemoprevention. However, tamoxifen use has been associated with adverse outcomes, and not all eligible women have a positive benefit/risk ratio...
  2. pmc Colorectal cancer risk prediction tool for white men and women without known susceptibility
    Andrew N Freedman
    Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, EPN 4005 MSC 7344, Bethesda, MD 20892 7344, USA
    J Clin Oncol 27:686-93. 2009
    ....
  3. ncbi request reprint Cancer risk prediction models: a workshop on development, evaluation, and application
    Andrew N Freedman
    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 7344, USA
    J Natl Cancer Inst 97:715-23. 2005
    ....
  4. pmc Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation
    Andrew N Freedman
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7393, USA
    J Natl Cancer Inst 102:1698-705. 2010
    ....
  5. ncbi request reprint US physicians' attitudes toward genetic testing for cancer susceptibility
    A N Freedman
    Division of Cancer Control and Population Sciences, National Cancer Institute NIH, EPN 4005 MSC 7344, 6130 Executive Boulevard, Bethesda, MD 20892 7344, USA
    Am J Med Genet A 120:63-71. 2003
    ..Results of this national survey underscore the need to provide physicians with clear guidelines on the use of genetic cancer susceptibility tests and effective medical training on their appropriate implementation...
  6. pmc Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians
    L Wideroff
    Applied Research Program Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 7344, USA
    J Med Genet 42:749-55. 2005
    ....
  7. ncbi request reprint What factors are associated with diagnostic follow-up after abnormal mammograms? Findings from a U.S. National Survey
    K Robin Yabroff
    Health Services and Economics Branch Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda, MD 20892 7344, USA
    Cancer Epidemiol Biomarkers Prev 13:723-32. 2004
    ....
  8. pmc Five-year and lifetime risk of breast cancer among U.S. subpopulations: implications for magnetic resonance imaging screening
    Barry I Graubard
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 19:2430-6. 2010
    ..Because MRI screening is costly and has limited specificity, estimates of the numbers of U.S. women with ≥20% breast cancer risk would be useful...
  9. pmc Laypersons' responses to the communication of uncertainty regarding cancer risk estimates
    Paul K J Han
    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA
    Med Decis Making 29:391-403. 2009
    ..To explore laypersons' responses to the communication of uncertainty associated with individualized cancer risk estimates and to identify reasons for individual differences in these responses...
  10. doi request reprint Conceptual problems in laypersons' understanding of individualized cancer risk: a qualitative study
    Paul K J Han
    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA
    Health Expect 12:4-17. 2009
    ..To explore laypersons' understanding of individualized cancer risk estimates, and to identify conceptual problems that may limit this understanding...
  11. ncbi request reprint Physician use of genetic testing for cancer susceptibility: results of a national survey
    Louise Wideroff
    National Cancer Institute, Division of Cancer Control and Population Sciences, Bethesda, Maryland 20892 7344, USA
    Cancer Epidemiol Biomarkers Prev 12:295-303. 2003
    ..39; 95% CI, 0.23-0.66%). These findings underscore the importance of establishing effective clinical approaches to test use and promoting physician education to facilitate communication with patients about cancer genetics...
  12. pmc Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
    Asad Umar
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Natl Cancer Inst 96:261-8. 2004
    ....
  13. ncbi request reprint Awareness of genetic testing for increased cancer risk in the year 2000 National Health Interview Survey
    Louise Wideroff
    National Cancer Institute, Division of Cancer Control and Population Sciences, National Institutes of Health, Bethesda, MD 20892 7344, USA
    Community Genet 6:147-56. 2003
    ..This study explores factors associated with differential awareness of genetic tests for increased cancer risk in the US...
  14. pmc Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women
    Erika A Waters
    Cancer Prevention Fellowship Program, Center for Cancer Training, Health Communication and Informatics Research Branch Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 19:443-6. 2010
    ..Tamoxifen can reduce the risk of developing invasive estrogen receptor-positive breast cancer by 49%, but it is unknown how many women in the United States are taking tamoxifen for primary prevention of breast cancer...
  15. ncbi request reprint Prevalence and correlates of repeat mammography among women aged 55-79 in the Year 2000 National Health Interview Survey
    William Rakowski
    Department of Community Health and The Center for Gerontology and Health Care Research, Brown University, Providence, RI 02912, USA
    Prev Med 39:1-10. 2004
    ..This study examines the prevalence and cross-sectional correlates of repeat mammography, among women aged 55-79, using a 12-month (N = 3,502) and a 24-month interval (N = 3,491)...
  16. ncbi request reprint Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility
    Susan Thomas Vadaparampil
    Health Outcomes and Behavior Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Am J Med Genet A 135:41-6. 2005
    ..At that time, one-quarter of the physicians considered advertisements to play an important role in their clinical decision making, suggesting attention to other sources of information and additional factors...